FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections
The US Food and Drug Administration (FDA) has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for CRESEMBA.
The US Food and Drug Administration (FDA) has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for CRESEMBA.
What's Your Reaction?
